Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004
Groton, CT, June 15, 2022 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the...
Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors
Groton, CT, December 14, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced today...
Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic
Groton, CT, November 22, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced...
MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004
Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...
Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury
Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced...
Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations
Lisa Manna, RN, MBA
Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative...
Astrocyte Pharmaceuticals Raises $6M Series A to Advance Next Generation Stroke and TBI Treatment to the Clinic
Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...
Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board...
Astrocyte Pharmaceuticals Presents NHP Stroke Study at International Stroke Conference
Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study
today at the International Stroke Conference in Los Angeles demonstrating...
Jeffrey L. Saver to Chair Astrocyte Pharmaceuticals’ Clinical Advisory Board
Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory...